Is cemiplimab available in China and the status of its listing and channel availability in China

Cemiplimab (Cemiplimab) is currently not available for purchase through formal channels in the country. The original version of the drug has not yet been launched in China, nor has it been included in the medical insurance catalog. Therefore, domestic hospitals and pharmacies are unable to provide legal procurement channels. If patients urgently need medication, they can only pay attention to the supply situation in overseas markets. However, they need to pay attention to the fact that cross-border drug purchase involves legal, transportation, cold chain and other issues, and the risks are higher.

In terms of listing in China, cimepilimab is still in the approval stage or waiting period for clinical introduction. Although it has been approved in the United States and Europe for the treatment of locally advanced or metastatic cutaneous squamous cell carcinoma and other indications, no official marketing announcement has been made in China. Due to strict requirements for drug approval, import registration and clinical trial data, it is expected that it will be difficult to make it widely available in the country in the short term.

Regarding channel acquisition, overseas markets are currently the main source of supply of cimepilimab. The common specifications of the American version and the European version of the original drug are 350mg/7mL (50mg/mL). Each box may be sold for between 40,000 and 100,000 yuan, and the price fluctuates due to exchange rates and supply conditions. If patients purchase drugs through overseas channels, they must ensure that the source of the drugs is legal and reliable, and follow cold chain transportation and storage requirements to ensure drug efficacy and safety.

In addition, there are currently no generic versions of cimepilimab on the market. Original drugs are exclusively supplied in overseas markets, making the drugs more expensive and difficult to obtain. If domestic patients consider using this drug, they should fully evaluate their efficacy needs, financial affordability, and safety risks, and formulate a medication plan under the guidance of a professional doctor to ensure the scientific nature of treatment and medication safety.

Keyword tags: cimepilimab, domestic purchase, marketing status, PD-1 inhibitor, cutaneous squamous cell carcinoma, overseas drug purchase, original research drug.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/?term=cemiplimab